Nanjing Leads Biolabs Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	213.22	177.26	-	8.87
Revenue Growth	-	-	-	-
Cost of Revenue	-	-	-	3.19
Gross Profit	213.22	177.26	-	5.68
Selling, General & Admin	88.24	82.7	87.69	38.05
Research & Development	348.3	289.09	185.68	230.86
Operating Expenses	436.54	371.79	273.38	268.91
Operating Income	-223.32	-194.53	-273.38	-263.23
Interest Expense	-7.88	-7.19	-5.76	-1.4
Interest & Investment Income	48.79	29.56	8.29	6.55
Currency Exchange Gain (Loss)	-	-	2.04	2.77
Other Non Operating Income (Expenses)	-66.06	-24.28	7.96	3.96
EBT Excluding Unusual Items	-248.46	-196.43	-260.85	-251.35
Gain (Loss) on Sale of Investments	0.11	0.54	1.72	6.44
Other Unusual Items	-	-	-42.08	-117.33
Pretax Income	-248.35	-195.89	-301.22	-362.25
Income Tax Expense	18.61	15.53	-	-
Net Income	-266.96	-211.42	-301.22	-362.25
Net Income to Common	-266.96	-211.42	-301.22	-362.25
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	194	174	150	145
Shares Outstanding (Diluted)	194	174	150	145
Shares Change	25.81%	16.10%	3.56%	-
EPS (Basic)	-1.37	-1.21	-2.01	-2.50
EPS (Diluted)	-1.37	-1.21	-2.01	-2.50
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-	-162.65	-121.79	-204.41
Free Cash Flow Per Share	-	-0.93	-0.81	-1.41
Gross Margin	100.00%	100.00%	-	64.07%
Operating Margin	-104.73%	-109.75%	-	-2969.26%
Profit Margin	-125.20%	-119.27%	-	-4086.28%
Free Cash Flow Margin	-	-91.76%	-	-2305.84%
EBITDA	-208.43	-178.9	-253.13	-243.49
EBITDA Margin	-97.75%	-100.92%	-	-
D&A For EBITDA	14.88	15.64	20.24	19.74
EBIT	-223.32	-194.53	-273.38	-263.23
EBIT Margin	-104.73%	-109.75%	-	-